一种新型的抗CD47纳米体四聚合物用于癌症治疗
Nataliya M Ratnikova1,2, Yulia Kravchenko1, Anna Ivanova1,3
1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.
Antibodies (Basel, Switzerland)
|January 22, 2024
概括
针对CD47的工程纳米体显示出癌症免疫治疗的前景. 这些小的,高亲和度的分子有效地触发瘤细胞的破坏和亡,为传统抗体提供了具有成本效益的替代品.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- CD47在瘤中过度表达,通过SIRPα相互作用促进免疫逃避.
- 针对CD47的常规单克隆抗体在尺寸和成本上都有局限性.
- 由于其独特的特性,纳米体提供了一个潜在的治疗替代方案.
研究的目的:
- 设计和描述一个高亲和度的纳米体,以CD47-SIRPα轴为目标.
- 评估抗CD47纳米体及其衍生物在癌症模型中的治疗潜力.
主要方法:
- 从免疫阿尔帕卡菌体库中分离一个VHH纳米体.
- 构建一个基于斯特雷普塔维丁的四聚体纳米体衍生物.
- 在体外和体内测试以评估细胞形成,亡诱导和疗效.
主要成果:
- 工程纳米体对SIRPα表现出纳米分子亲和力,超过B6H12.2抗体的亲和力.
- 纳米体和衍生物有效地刺激瘤细胞细胞分裂,并诱导U937细胞的亡.
- 在体外和体外癌症模型中都证明了有效性.
结论:
- 设计的抗CD47纳米体是癌症免疫治疗的有力候选者.
- 基于纳米体的疗法提供了一种更有效和更具成本效益的方法来破坏CD47-SIRPα通路.
- 在瘤治疗中独立或组合使用的潜力.
相关概念视频
01:27Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K